First, we found a robust upregulation of proinflammatory cytokines, interleukins, tumor necrosis factor, and GFAP, in the CSF of SOD1‐ALS patients on tofersen for 12 months compared with baseline (Fig. S13). The gene discussed is GFAP; the disease is amyotrophic lateral sclerosis.